UBS raises Certara stock price target on software demand strength

UBS raised its price target for Certara (CERT) to $13.00 from $10.00, citing strong software demand. Software bookings rose 15% YoY, and revenue grew 11% in the quarter. Management raised revenue guidance. The stock is up 94.6% over six months. Q3 2026 revenue was $94.9M, beating estimates, with software sales up 11%.

Original reporting
Published Nov 6, 2026, 8:11 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 8:18 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CERT
Bullish
high confidence
Mentioned
$CERT
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CERTBullishMed
01

Why it matters

The upgrade could attract new buying interest, especially from investors focused on high‑growth biotech software firms.

02

Market read

Analyst upgrade may drive short‑term buying pressure in Certara and influence sentiment in the broader biotech software niche.

03

What to watch

Potential headwinds from regulatory changes or competition in drug‑development software could temper growth.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

UBS analysts cite a 15% YoY rise in software bookings and an 11% software revenue increase in Q3 2026, prompting a price target lift.

Company-level read

Ticker impact

$CERTBullishHigh confidence
Context

UBS raised its price target on Certara to $13 from $10 and reported stronger software revenue and guidance, providing fresh analyst coverage.

Expected impact

likely upward pressure as the market prices in the higher target and improved software outlook

Evidence & confidence

The price target increase and guidance raise suggest better near‑term earnings, prompting traders to consider buying on potential upside.

Market effects

Positive signal for the biotech software sector as Certara's software bookings accelerate.

U.S. biotech stocks may see modest gains from the upgrade.

Limited to investors tracking U.S. biotech and software service providers.

Counterpoint

The upgrade may be premature if services bookings remain weak and the software re‑acceleration stalls.

Key entities

  • Certara Inc.

    Provider of drug‑development software and services.

  • UBS

    Investment bank that raised Certara's price target.

Related articles

$CERTMedAI 8/10

An Idle Mill and Old Open Pits Draw a New Plan in Southern Argentina

Cerrado Gold Inc. (TSX.V: CERT) (OTCQX: CRDOF) acquired a past-producing mine in Argentina for $20M, aiming to restart operations by 2027. The mine previously produced 1.4M gold equivalent ounces, with peak output of 137,500 ounces in 2011. The company plans a $40,000m drill program for a resource estimate, funded by its existing Santa Cruz operation.

$CERTHigh

Certara Software Revenue Jumps 11% as Services Decline

Certara Inc. (CERT) reported Q3 2026 software revenue growth of 11% to $48.8M, while services revenue declined 2% to $46.1M. Total revenue rose 4% to $94.9M, and net loss narrowed to $3.6M. Adjusted EBITDA increased 6% to $30.2M. The company maintained its full-year revenue growth forecast of 2-3% and updated its adjusted earnings outlook to 31-34 cents per share.

$CERTMed

Why Did Certara (CERT) Shares Climb After Its Latest Update?

Certara (CERT) reported Q3 2026 revenue of $94.9M, up from $90.89M a year earlier, with net income of $5.59M. However, nine-month revenue of $282.26M showed a net loss of $58.44M. Shares rose 9.83% in one day and 35.94% in 30 days, with a year-to-date return of 39.36%. The company's fair value is estimated at $8.71, suggesting a 40% overvaluation. Certara's AI-driven platforms and acquisitions aim to boost revenue and margins.

$CERTMed

Certara Inc (CERT) Q3 2026 Earnings Call Highlights: Software Growth Accelerates as Margins Expand

Certara Inc (CERT) reported Q3 2026 earnings with software revenue growth of 11% but services revenue declined 2% YoY to $46.1M. Full-year 2026 revenue growth guidance was narrowed to 2%-3%. CEO Jon Resnick highlighted cost savings exceeding $12M and strong software demand across customer tiers. The company is transitioning to a cloud-based model and investing in AI initiatives, expecting growth in 2027. GAAP net loss was $3.6M, and adjusted EPS remained flat at $0.09 YoY.

$CERTMed

Certara, Inc. Q3 2026 Earnings Call Summary

Certara reported 11% organic software revenue growth in Q3 2026, its first double-digit increase in two years. The company divested its Regulatory and Medical Writing business to focus on high-growth areas and reorganized operations. Management expects 2%-3% full-year revenue growth, with software outperforming services. AI capabilities and APAC market expansion are seen as growth drivers for 2027.

$CERTHighAI 8/10

Certara Q3 Earnings Call Highlights

Certara reported Q3 bookings up 4% to $92.5M, with a net loss of $3.6M. The company is accelerating cloud conversions and AI integration, expecting growth impacts in 2027. It narrowed FY2026 revenue growth outlook to 2-3% and updated adjusted earnings outlook to $0.31-$0.34 per share. Certara has $214.9M in cash and $100M available under its revolving credit facility.